Nanotechnology-based drug delivery systems for Alzheimer's disease management: Technical, industrial, and clinical challenges

Advances in Molecular Imaging of Locally Delivered Targeted Therapeutics for Central Nervous System Tumors

“…Each is characterized by specific properties that ultimately determine their therapeutic potential. Their characterization is so vast that it by far exceeds the scope of this review and should be addressed elsewhere [66,101,102,103,104]; briefly, specific properties determine tissue penetration (including ability to bypass the BBB), loading/unloading potential, and imaging possibility. Theranostic nanocarriers can represent a three-part system composed of the carrier itself, the loaded therapeutic(s), and the imaging agent [105,106,107], or two part system where carrier is also an imaging agent (for e.g., superparamagnetic iron oxide nanoparticles; these agents, by virtue of the molecular structure containing paramagnetic iron oxide, are MRI-active agents and, as such, do not need coupling with other tracers, constituting a bivalent system [108]).…”

Polyelectrolyte nanocontainers: Controlled binding and release of indomethacin

“…The development of medicine, pharmacology, and biotechnologies resulted in the growing interest in the design of new systems for encapsulation and delivery of drugs. Recent investigations showed that the objects of supramolecular chemistry represented by amphiphilic compounds and biocompatible polymers can provide background for the design of various types of nanocontainers (micelles, nano-and microemulsions, liposomes, polyelectrolyte capsules, and others), which can retain drugs and preserve them from adverse environmental factors along with their target delivery and long-standing effect [1][2][3][4][5][6][7][8][9]. These nanocontainers possess several advantages, among which following can be highlighted: (1) simplicity and high processability;…”

Diferenciação neuronal e efeito neuroprotetor de novas moléculas híbridas inibidoras de acetilcolinesterase em modelo SH-SY5Y

“…Os peptídeos Aβ são derivados do processamento proteolítico anormal de proteínas APP (amyloid precursor protein) por enzimas de processamento (β-e γ-secretases) resultando no acúmulo de proteínas amiloides Aβ(1 -40) e Aβ(1 -42), que se agregam progressivamente, no entanto, Aβ (1-42) é mais fibrilogênica; portanto, está mais associada ao estado de doença (Gorlovoy et al, 2009;Wen et al, 2017). A hiperfosforilação anormal da proteína tau ocasiona um tipo específico de neurodegeneração lenta e progressiva, levando a degeneração neurofibrilar, observada como emaranhados neurofibrilares, fios neuropilares e neuritos distróficos (Iqbal et al, 2009 Wands, 2008;Mandelkow et al, 2003).…”

“…As principais estratégias terapêuticas na DA visam controlar ou retardar a progressão da doença ou de seus sintomas (Wen et al, 2017 (Gao et al, 2014;Zhang et al, 2016). Esses dados apontam a necessidade de buscar novas moléculas que sejam mais eficientes e com menos efeitos colaterais para o tratamento de pacientes com DA (Luo et al, 2015).…”

“…pacientes com DA leve ou moderada. Dentre esses, os medicamentos donepezila, rivastigmina e galantamina(Alonso et al, 2005) são comercializados como formulações orais (exceto rivastigmina, que também está disponível como um adesivo transdérmico)(WEN et al, 2017). Há também outros fármacos como memantina, que atua nos receptores NMDA…”